Tivozanib: VEGFR tyrosine kinase inhibitor angiogenesis inhibitor oncolytic

Drugs of the Future

Volumn 34, Issue 10, 2009, Pages 793-796

  Campas C ^a   Bolos J ^a   Castaner R ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; KRN 951; PACLITAXEL; RAPAMYCIN; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BRAIN CANCER; BRAIN HEMORRHAGE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOMATOUS PERITONITIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL TUMOR; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DYSPHONIA; ENDOTHELIUM CELL; FATIGUE; GASTROINTESTINAL TUMOR; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN TARGETING; PROTEINURIA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; TUMOR XENOGRAFT;

EID: 84930542030     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.10.1417872     Document Type: Review

References (27)

1. Matsunaga, N., Nakajima, T., Yoshino, A., Yoshida, S. (Kirin Brewery Co., Ltd.). N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N′-(5- methyl-3-isoxazolyl)urea salt in crystalline form. EP 1559715, US 2006052415, WO 2004035572.
2. Suzuki, R. et al. Structure-activity relationship and antitumor activities of azolyl quinoline-urea derivatives as novel orally active selective VEGF receptor tyrosine kinase inhibitors. 23rd Med Chem Symp (Nov 24-26, Tsukuba) 2004, Abst 1P-30.
3. Kubo, K., Sakai, T., Hasegawa, K., Fujiwara, Y., Isoe, T., Nagao, R. (Kirin Brewery Co., Ltd.). Quinoline derivative having ozolyl group and quinazoline derivative. EP 1382604, EP 1652847, JP 2003012668, JP 2004224800, US 2003087907, US 6821987, WO 2002088110.
4. Kowanetz, M., Ferrara, N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res 2006, 12(17): 5018-22.
5. Veikkola, T., Karkkainen, M., Claesson-Welsh, L., Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000, 60(2): 203-12.
6. Prat, A., Casado, E., Cortés, J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007, 13(44): 5857-66.
7. Gutierrez, M., Giaccone, G. Antiangiogenic therapy in nonsmall cell lung cancer. Curr Opin Oncol 2008, 20(2): 176-82.
8. Rini, B.I. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: Current status and future directions. Clin Cancer Res 2007, 13(4): 1098-106.
9. Guilbaud, N., Hasegawa, K., Kubo, K. et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006, 66(18): 9134-42.
10. Taguchi, E., Nakamura, K., Takahasi, K., Kamishohara, M., Miura, T., Shibuya, M., Isoe, T. A novel orally active inhibitor of VEGF receptor tyrosine kinases KRN951: Anti-angiogenic and anti-tumor activity against human solid tumors. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 2575.
11. Nakamura, K., Taguchi, E., Takahashi, K., Kamishohara, M., Miura, T., Shibuya, M., Isoe, T. In vitro selectivity and potency of KRN951, a novel inhibitor of VEGF receptor tyrosine kinases. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 2571.
12. Nakamura, K., Taguchi, E., Miura, T. et al. The VEGF receptor inhibitor KRN951 decreases vascular permeability in tumors and inhibits tumor growth: An analysis using dynamic contrast-enhanced magnetic resonance imaging. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 5843.
13. Taguchi, E., Nakamura, K., Miura, T., Shibuya, M., Isoe, T. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci 2008, 99(3): 623-30.
14. Robinson, M., Lin, J., Yang, H. et al. Combination treatment of VEGFR inhibitor AV-951 and rapamycin reveals distinct mechanisms of each agent's anti-tumor activity. Eur J Cancer Suppl [20th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Oct 21-24, Geneva) 2008] 2008, 6(12): Abst 53.
15. Lin, J., Kannan, K., Heyer, J. et al. Variation in response to VEGFR inhibitor AV-951 across a population of genetically engineered breast tumors reveals distinct phenotypic classes of resistance. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 2499.
16. Murakami, M., Iwai, S., Hiratsuka, S., Yamauchi, M., Nakamura, K., Iwakura, Y., Shibuya, M. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 2006, 108(8): 1849-56.
17. Eskens, F.A., Planting, F.A., Van Doorn, L. et al. An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 2034.
18. Eskens, F.A.L.M., De Jonge, M.J.A., Van doorn, L. et al. Phase I and pharmacological study of KRN951, a potent VEGFR tyrosine kinase inhibitor given in a 4 week on, 2 week off schedule in patients with advanced solid tumors. Eur J Cancer Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006,4(12): Abst 38.
19. Isoe, T. From drug discovery to the clinic; experiences with KRN951, a VEGF receptor tyrosine kinase inhibitor. 66th Annu Meet Jpn Cancer Assoc (Oct 3-5, Yokohama) 2007, Abst S17-6.
20. Bhargava, P., Esteves, B., Nosov, D.A. et al. Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 5032.
21. Bhargava, P., Esteves, B., Lipatov, O.N. et al. Activity and safety of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial. Genitourin Cancers Symp (Feb 26-28, Orlando) 2009, Abst 283.
22. A study of AV-951, an oral VEGF receptor tyrosine kinase inhibitor, in the treatment of renal cell carcinoma (NCT00502307). ClinicalTrials.gov Web site, September 28, 2009.
23. An open-label study of QD oral administration of AV-951 in subjects with non-small cell lung cancer (NSCLC) (NCT00826878). ClinicalTrials.gov Web site, September 28, 2009.
24. A phase 1b/2a, open-label, multi-center study of AV-951 in combination with paclitaxel in subjects with advanced or metastatic breast cancer (NCT00717340). ClinicalTrials.gov Web site, September 28, 2009.
25. Study of AV-951 plus FOLFOX6 in subjects with advanced colorectal cancer and other gastrointestinal cancers (NCT00660153). ClinicalTrials.gov Web site, September 28, 2009.
26. A phase 1b, open-label, dose-finding study to evaluate the safety of AV-951 in combination with temsirolimus in subjects with metastatic renal cell carcinoma (NCT00563147). ClinicalTrials.gov Web site, September 28, 2009.
27. Study of KRN951 in patients with solid tumors (NCT00970411). ClinicalTrials.gov Web site, September 28, 2009.